KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...

Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...